Edgewise Therapeutics, Inc.
EWTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for EWTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EWTX
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule precision medicines for severe muscle diseases, including neuromuscular and cardiac conditions, with lead programs in hypertrophic cardiomyopathy (HCM) and other muscle disorders.
Key risk: No approved products
BioSniper Score
Based on 6 of 6 signals
Market Cap
$4.64B
Cash Runway
13.6 moLead Asset
EDG-7500 (Phase 1)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 9 clinical trials · 1 catalyst for Edgewise Therapeutics, Inc..
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule precision medicines for severe muscle diseases, including neuromuscular and cardiac conditions, with lead programs in hypertrophic cardiomyopathy (HCM) and other muscle disorders.
- Edgewise has built a proprietary, muscle-focused drug discovery platform that uses high-throughput translatable systems to identify small-molecule sarcomere modulators [sec_mda · as of 2026-02-26].
- In June 2026, the company announced positive topline data from its multipart Phase 2 trial (CIRRUS-HCM) for EDG-7500 in hypertrophic cardiomyopathy and plans to initiate a Phase 3 trial in Q4 2026 [sec_mda · as of 2026-08-06].
- As of June 30, 2026, Edgewise reported cash and equivalents of $72.3 million, shareholders' equity of $522.3 million, and a net loss of $57.3 million for the quarter [latest reported financials].
- The company has incurred significant operating losses since inception, with an accumulated deficit of $419.4 million as of March 31, 2025, and expects to continue incurring losses as it advances its pipeline [sec_mda · as of 2025-05-08].
What works
- Edgewise's lead candidate EDG-7500 has generated positive Phase 2 topline data in HCM, supporting advancement to a Phase 3 trial, indicating potential clinical differentiation [sec_mda · as of 2026-08-06].
- The company's proprietary drug discovery platform has produced a library of novel sarcomere modulators with broad pharmacological properties, providing a foundation for multiple pipeline programs [sec_mda · as of 2026-02-26].
- Edgewise has raised substantial capital through public offerings, including $793.7 million from follow-on and registered direct offerings, providing financial flexibility for ongoing development [sec_mda · as of 2026-02-26].
What to weigh
- Edgewise has no approved products and has incurred significant net losses, with a net loss of $106.3 million for the six months ended June 30, 2026, and expects losses to continue [sec_mda · as of 2026-08-06].
- The company's cash and equivalents of $72.3 million as of June 30, 2026, may require additional financing to fully fund late-stage trials and potential commercialization [latest reported financials].
- Clinical development of EDG-7500 and other candidates is subject to inherent risks of delay, regulatory hurdles, and unforeseen expenses common in biotech [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
Positive Phase 2 topline data for EDG-7500 in HCM
“In June 2026, we announced positive topline data for our multipart Phase 2 trial with EDG-7500 for people with HCM (CIRRUS-HCM)”
SEC MD&A · August 6, 2026
Planned Phase 3 initiation for EDG-7500
“are planning to initiate a Phase 3 trial for EDG-7500 in the fourth quarter of 2026”
SEC MD&A · August 6, 2026
Significant net losses and accumulated deficit
“Our net losses were $57.3 million and $106.3 million for the three and six months ended June 30, 2026, respectively”
SEC MD&A · August 6, 2026
Cash position and financing history
“We believe that our existing cash and cash equivalents and marketable securities of $530.1 million will enable us to fund our planned operating expenses and capital expenditure requirements through at least the next 12 months.”
SEC MD&A · February 26, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · sevasemten — Phase 2 Readout: sevasemten — Topline data from the Phase 2 trial of sevasemten will provide key efficacy and safety signals for this candidate.
Risks & what to watch (4)›
Key risks
- No approved products — Edgewise has no commercial products and relies on successful clinical development and regulatory approval [sec_mda · as of 2026-08-06].
- History of operating losses — The company has incurred significant losses since inception, with an accumulated deficit of $419.4M as of March 31, 2025 [sec_mda · as of 2025-05-08].
- Need for additional capital — Cash of $72.3M as of June 30, 2026 may be insufficient to fund all planned activities without further financing [latest reported financials].
- Clinical and regulatory delays — Development of EDG-7500 and other candidates is subject to delays, complications, and regulatory uncertainties [sec_mda · as of 2026-05-07].
What to watch
- Initiation of Phase 3 trial for EDG-7500 in HCM, planned for Q4 2026 [sec_mda · as of 2026-08-06].
- Phase 2 topline readout for sevasemten, expected by end of 2026 [upcoming catalysts].
- Cash runway and potential need for additional financing as losses continue [latest reported financials].
- Progress of preclinical programs, including novel cardiometabolic targets [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Edgewise Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Edgewise Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
13.6 months
D/E 0.07 · 0% dilution
Lead: Phase 2
2 candidates
1 upcoming, next in ~123d
0 buys · 27 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
215
Total value held
$3.83B
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 15,518,492 | $488.8M |
| janus henderson group plc | 11,831,112 | $372.6M |
| ra capital management, l.p. | 10,428,437 | $328.5M |
| perceptive advisors llc | 8,847,948 | $278.7M |
| vanguard capital management llc | 7,576,322 | $238.7M |
| baker bros. advisors lp | 6,575,940 | $207.1M |
| blackrock, inc. | 6,472,991 | $203.9M |
| novo holdings a/s | 5,350,000 | $168.5M |
| driehaus capital management llc | 4,477,942 | $141.1M |
| cormorant asset management, lp | 3,260,000 | $102.7M |
Showing top 10 of 215 institutional holders of Edgewise Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 10.3%
- Days to cover
- 10.7
- Shares short
- 9,448,351
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EWTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Edgewise Therapeutics, Inc.?
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule precision medicines for severe muscle diseases, including neuromuscular and cardiac conditions, with lead programs in hypertrophic cardiomyopathy (HCM) and other muscle disorders.
What is Edgewise Therapeutics, Inc.'s lead drug candidate?
Edgewise Therapeutics, Inc.'s most advanced tracked candidate is EDG-7500 (Phase 1) for Hypertrophic Cardiomyopathy; Hepatic Impairment (HI); Renal Impairments.
What is Edgewise Therapeutics, Inc.'s next catalyst?
Edgewise Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: sevasemten" — expected December 31, 2026.
Who is the CEO of Edgewise Therapeutics, Inc.?
Dr. Kevin Koch Ph.D. is the chief executive officer of Edgewise Therapeutics, Inc. (EWTX).
Where is Edgewise Therapeutics, Inc. headquartered?
Edgewise Therapeutics, Inc. (EWTX) is headquartered in Boulder, CO, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.